Free Trial
NASDAQ:BIS

ProShares UltraShort Nasdaq Biotechnology (BIS) Price, Holdings, & News

$16.04 +0.06 (+0.38%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$16.05 +0.01 (+0.06%)
As of 02/21/2025 04:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS)

Key Stats

Today's Range
$15.63
$16.10
50-Day Range
$15.65
$18.80
52-Week Range
$14.05
$21.10
Volume
10,998 shs
Average Volume
8,832 shs
Market Capitalization
$3.21 million
Assets Under Management
$3.25 million
Dividend Yield
4.18%
Net Expense Ratio
0.95%
Aggregate Rating
N/A

ETF Overview

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day. The Fund invests in equity securities and derivatives that have similar daily performance characteristics as twice (200%) the daily return of the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. ProShare Advisors LLC is the investment advisor of the Fund.

ProShares UltraShort Nasdaq Biotechnology Expenses

TypeBISHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFs
Management Fee0.75%0.57%0.56%0.51%0.53%
Other Expenses1.22%0.30%0.50%0.47%0.53%
Total Expense1.97%0.70%0.72%0.67%0.71%
Fee Waiver-1.02%-0.45%-0.50%-0.32%-0.56%
Net Expense0.95%0.61%0.62%0.60%0.60%
Receive BIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProShares UltraShort Nasdaq Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

BIS ETF News Headlines

BIS ProShares UltraShort Nasdaq Biotechnology ETF
Watch This Robotics Demo Before March 17th
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
See More Headlines

BIS ETF - Frequently Asked Questions

ProShares UltraShort Nasdaq Biotechnology's stock was trading at $18.19 on January 1st, 2025. Since then, BIS shares have decreased by 11.8% and is now trading at $16.04.
View the best growth stocks for 2025 here
.

ProShares UltraShort Nasdaq Biotechnology's stock reverse split on Tuesday, August 18th 2020. The 1-4 reverse split was announced on Tuesday, August 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 17th 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

ProShares UltraShort Nasdaq Biotechnology's top institutional shareholders include Jane Street Group LLC (19.35%) and Tower Research Capital LLC TRC (2.66%).
View institutional ownership trends
.

Shares of BIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ProShares UltraShort Nasdaq Biotechnology investors own include Micron Technology (MU), Inovio Pharmaceuticals (INO), Sanofi (SNY), Intel (INTC), Meta Platforms (META), NVIDIA (NVDA) and Advanced Micro Devices (AMD).

Fund Details

Issuer
ProShares
Fund Name
ProShares UltraShort Nasdaq Biotechnology
Tax Classification
Regulated Investment Company
Current Symbol
NASDAQ:BIS
Inception Date
4/6/2010
Fund Manager
Michael Neches, Tarak Dave

Fund Focus

Asset Class
Equity
Benchmark
Nasdaq Biotech Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
17

Fund Statistics

Assets Under Management
$3.25 million
Average Daily Volume
$11,038.40
Discount/Premium
0.02%
Leveraged
-2.00

Administrator, Advisor and Custodian

Administrator
J.P. Morgan Investor Services Co.
Advisor
ProShare Advisors LLC
Custodian
JPMorgan Chase Bank, N.A.
Distributor
SEI Investments Distribution Co.
Transfer Agent
JPMorgan Chase Bank, N.A.
Trustee
N/A
Lead Market Maker
Virtu Financial

Options

Optionable
N/A
Short Interest
8,600 shs

Miscellaneous

Beta
-1.41
Creation Unit
50,000
Creation Fee
$250.00
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

Top 8 BIS Holdings

  • NET OTHER ASSETS (LIABILITIES)
    Holding Weight: 0.00%
  • TREASURY BILL
    Holding Weight: 0.00%
  • NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NA
    Holding Weight: -6.38%
  • NASDAQ BIOTECHNOLOGY INDEX SWAP MORGAN STANLEY & CO. INTERNATIONAL PLC
    Holding Weight: -14.97%
  • NASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NA
    Holding Weight: -20.44%
  • NASDAQ BIOTECHNOLOGY INDEX SWAP UBS AG
    Holding Weight: -39.85%
  • NASDAQ BIO INDEX SWAP BNP PARIBAS
    Holding Weight: -42.06%
  • NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALE
    Holding Weight: -76.83%

This page (NASDAQ:BIS) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners